Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aziyo Biologics, Inc. (AZYO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.97-0.01 (-0.17%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.98
Open6.20
Bid5.90 x 800
Ask6.28 x 900
Day's Range5.90 - 6.24
52 Week Range5.07 - 18.20
Volume10,886
Avg. Volume17,350
Market Cap61.06M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
  • GlobeNewswire

    Aziyo Biologics to Participate in Upcoming Virtual Investor Conferences

    SILVER SPRING, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the company will participate in two upcoming virtual investor conferences. Event: Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services ForumFormat: 1x1 MeetingsDate: Thursday, November 18, 2021 Eve

  • Zacks

    Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates

    Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aziyo Biologics Reports Third Quarter 2021 Financial Results

    SILVER SPRING, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2021. “Despite the challenges faced during the quarter, the long-term value proposition of our regenerative medicine portfolio remains intact, as evidence

Advertisement
Advertisement